Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
Chino, A., Masuda, N., Amano, Y., Honbou, K., Mihara, T., Yamazaki, M., Tomishima, M.(2014) Bioorg Med Chem 22: 3515-3526
- PubMed: 24837154 
- DOI: https://doi.org/10.1016/j.bmc.2014.04.023
- Primary Citation of Related Structures:  
3WS8, 3WS9 - PubMed Abstract: 
In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reducing lipophilicity and introducing substituents, we acquired 35, which exhibited both improved metabolic stability and reduced CYP3A4 time-dependent inhibition.
Organizational Affiliation: 
Institute for Drug Discovery Research, 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. Electronic address: ayaka.chino@astellas.com.